Nls Pharmaceutics Ltd (NLSP) Stock Price, Quote & News

Company Profile

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience for the treatment of narcolepsy; and N...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 44 512 21 50

Fax: 41 44 512 21 51

Website: nlspharma.com

Address:

The Circle 6, Zurich, Switzerland

ThatDudeWithNoMoney Aug. 18 at 1:40 AM

$NLSP $ONCO $RSLS I just want to reiterate that none of what I posted matters. There are stocks that release dilution news and it skyrockets 500%. Every stock is a gamble, good news or bad news. You just gotta get lucky on picking the right one. Good luck tomorrow bulls. *This is strictly speculative insight and not financial advice*

0 · Reply

Kingjaff Aug. 17 at 4:37 PM

$ADN Take your profits to $NLSP

0 · Reply

Kingjaff Aug. 17 at 4:01 PM

$HCTI $IXHL $RAYA We ready for squeeze Monday 🔥Watching $NLSP for merge squeeze 🔥

1 · Reply

makedatbread88 Aug. 16 at 9:53 PM

Hope everyone has a good weekend. The rest of August into September is going to be massive folks. Mark this post I see all of these tickers having big moves from current prices. If you’re not in any of these it’s not too late to add come Monday. Amazing time to be in these tickers below going to be massive👇 $COEP $TLRY $NEOV $NLSP $TRNR

5 · Reply

Martian_Paradisee Aug. 16 at 7:02 PM

$GOVX $NLSP $MRNY $TNXP Does anybody follow M. Burry (from "The Big Short") portfolio for copy trade?

1 · Reply

lzrob Aug. 16 at 2:14 PM

$NLSP This is what I got from ChatGPT.... I haven't done a fact check but if there is anything that is incorrect please let me know.

2 · Reply

Pastures Aug. 16 at 11:09 AM

$NLSP How are you all playing this swing trade? Will you sell before or after the voting on the 25th of August? Or will you hold through until the merger is released? Thanks everyone! 😁

0 · Reply

ThatDudeWithNoMoney Aug. 16 at 8:29 AM

I'm not much of a ChatGPT guy but I gave in and asked what current merger plays would triple my position...and these are the stocks it listed: $NLSP $ONCO $RSLS Lets see how our hands play out. *This is strictly speculative insight and NOT financial advice*

2 · Reply

fisher04 Aug. 16 at 4:43 AM

$NLSP what is everyone’s pt for merger ?

1 · Reply

Jon117 Aug. 15 at 11:25 PM

$NLSP couple more buys and we’re in the green for the day

0 · Reply

NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy

Jun 30, 2025, 7:00 AM EDT - 6 weeks ago

NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing

Jun 16, 2025, 7:00 AM EDT - 2 months ago

NLS Pharmaceutics CEO Issues Letter to Shareholders

May 21, 2025, 7:30 AM EDT - 3 months ago

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting

Apr 15, 2025, 9:00 AM EDT - 4 months ago

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

Mar 31, 2025, 9:10 AM EDT - 4 months ago

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

Feb 27, 2025, 7:00 AM EST - 6 months ago

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

Feb 25, 2025, 9:05 AM EST - 6 months ago

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

Feb 10, 2025, 7:30 AM EST - 6 months ago

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

Jan 31, 2025, 7:30 AM EST - 7 months ago

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

Jan 30, 2025, 7:30 AM EST - 7 months ago

NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting

Jan 28, 2025, 7:30 AM EST - 7 months ago

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

Jan 16, 2025, 9:32 AM EST - 7 months ago

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

Jan 8, 2025, 7:42 AM EST - 7 months ago

NLS Pharmaceutics Ltd. and Kadimastem Ltd.

Dec 19, 2024, 7:30 AM EST - 8 months ago

NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment

Dec 4, 2024, 1:15 PM EST - 9 months ago

NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market

Dec 3, 2024, 7:40 AM EST - 9 months ago

NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders

Nov 18, 2024, 7:30 AM EST - 9 months ago

NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders

Nov 4, 2024, 7:00 AM EST - 10 months ago

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

Oct 28, 2024, 7:00 AM EDT - 10 months ago

NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements

Oct 21, 2024, 7:00 AM EDT - 10 months ago

NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence

Oct 15, 2024, 7:00 AM EDT - 10 months ago

NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules

Sep 25, 2024, 8:00 AM EDT - 11 months ago

NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split

Jul 29, 2024, 12:03 PM EDT - 1 year ago

Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump

Jul 29, 2024, 7:00 AM EDT - 1 year ago

NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge

Jun 28, 2024, 9:00 AM EDT - 1 year ago

NLS Pharmaceutics Announces Registered Direct Offering

Jun 27, 2024, 8:00 AM EDT - 1 year ago

NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments

Jun 25, 2024, 8:30 AM EDT - 1 year ago

Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements

Jun 11, 2024, 8:30 AM EDT - 1 year ago

NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)

Apr 19, 2024, 5:00 PM EDT - 1 year ago

NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing

Mar 22, 2024, 4:30 PM EDT - 1 year ago

NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering

Mar 20, 2024, 1:40 PM EDT - 1 year ago

NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering

Mar 20, 2024, 7:30 AM EDT - 1 year ago

NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform

Mar 14, 2024, 8:00 AM EDT - 1 year ago

NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance

Feb 23, 2024, 7:30 AM EST - 1 year ago

NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq

Jan 12, 2024, 4:30 PM EST - 1 year ago

Notice of Deficiency with Nasdaq Continued Listing Requirements

Dec 1, 2023, 7:30 AM EST - 1 year ago

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.

Nov 28, 2023, 7:30 AM EST - 1 year ago

NLS Pharmaceutics Announces Election of Additional Board Members

Nov 27, 2023, 8:30 AM EST - 1 year ago

NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia

Nov 16, 2023, 8:00 AM EST - 1 year ago

NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan

Oct 25, 2023, 4:30 PM EDT - 1 year ago

NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Oct 19, 2023, 5:00 PM EDT - 1 year ago

NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions

Oct 12, 2023, 9:40 AM EDT - 2 years ago

NLS Pharmaceutics Announces Company Update on Strategic Partnerships

Jul 3, 2023, 8:53 AM EDT - 2 years ago

NLS Pharmaceutics shares rise as narcolepsy treatment moves to phase 3 studies

Jul 3, 2023, 7:00 AM EDT - 2 years ago

NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol

Jun 30, 2023, 4:05 PM EDT - 2 years ago

NLS Pharmaceutics Releases the Results from its Annual General Meeting

Jun 30, 2023, 8:00 AM EDT - 2 years ago

NLS Pharmaceutics Company Update and Webcast Today Postponed

Jun 19, 2023, 7:30 AM EDT - 2 years ago

CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Jun 19, 2023, 7:10 AM EDT - 2 years ago

NLS Pharmaceutics Announces Company Update Webcast

ThatDudeWithNoMoney Aug. 18 at 1:40 AM

0 · Reply

Kingjaff Aug. 17 at 4:37 PM

$ADN Take your profits to $NLSP

0 · Reply

Kingjaff Aug. 17 at 4:01 PM

$HCTI $IXHL $RAYA We ready for squeeze Monday 🔥Watching $NLSP for merge squeeze 🔥

1 · Reply

makedatbread88 Aug. 16 at 9:53 PM

5 · Reply

Martian_Paradisee Aug. 16 at 7:02 PM

$GOVX $NLSP $MRNY $TNXP Does anybody follow M. Burry (from "The Big Short") portfolio for copy trade?

1 · Reply

lzrob Aug. 16 at 2:14 PM

$NLSP This is what I got from ChatGPT.... I haven't done a fact check but if there is anything that is incorrect please let me know.

2 · Reply

Pastures Aug. 16 at 11:09 AM

$NLSP How are you all playing this swing trade? Will you sell before or after the voting on the 25th of August? Or will you hold through until the merger is released? Thanks everyone! 😁

0 · Reply

ThatDudeWithNoMoney Aug. 16 at 8:29 AM

2 · Reply

fisher04 Aug. 16 at 4:43 AM

$NLSP what is everyone’s pt for merger ?

1 · Reply

Jon117 Aug. 15 at 11:25 PM

$NLSP couple more buys and we’re in the green for the day

0 · Reply

Jon117 Aug. 15 at 9:53 PM

$NLSP nice little correction after coming up from 1.70 will run next week forsure

2 · Reply

Kingjaff Aug. 15 at 8:54 PM

$OPEN Still holding half position and loading $NLSP for squeeze next week 🔥

0 · Reply

Rico999 Aug. 15 at 8:42 PM

$NLSP NLSP current partner Kadimastem has a stock price of.

0 · Reply

Richard3891 Aug. 15 at 7:58 PM

$NLSP in my opinion if you’re in your in enjoy the ride. If short well done on your 40 cents profit. But the big picture is kadimastem shares are $764.96 per share. Which means this could go to the moon!!!!

0 · Reply